A vesicular stomatitis pseudovirus expressing the surface glycoproteins of influenza A virus

Чересиз, С. В.; Kononova, A. A.; Razumova, Yu. V.; Dubich, Tatyana; Chepurnov, A. A.; Кущ, А А; Davey, Robert A.; Pokrovsky, Andrey G.

doi:10.1007/s00705-014-2127-y

Cited by 13 publications

(13 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there are multiple reports of pseudotyped viruses that are capable of a single round of infection after complementation with influenza virus HA (54)(55)(56)(57)(58), the pseudotypes are not capable of multiple cycles of replication. The recombinant VSV⌬G expressing an H5 HA and an N1 NA that we describe here is replication competent in tissue culture and generates single-dose protective immunity to a lethal H5N1 challenge in mice.…”

Section: Discussionmentioning

confidence: 99%

A Viable Recombinant Rhabdovirus Lacking Its Glycoprotein Gene and Expressing Influenza Virus Hemagglutinin and Neuraminidase Is a Potent Influenza Vaccine

Ryder

Buonocore

Vogel

et al. 2015

J Virol

View full text Add to dashboard Cite

The emergence of novel influenza viruses that cause devastating human disease is an ongoing threat and serves as an impetus for the continued development of novel approaches to influenza vaccines. Influenza vaccine development has traditionally focused on producing humoral and/or cell-mediated immunity, often against the viral surface glycoproteins hemagglutinin (HA) and neuraminidase (NA). Here, we describe a new vaccine candidate that utilizes a replication-defective vesicular stomatitis virus (VSV) vector backbone that lacks the native G surface glycoprotein gene (VSV⌬G). The expression of the H5 HA of an H5N1 highly pathogenic avian influenza virus (HPAIV), A/Vietnam/1203/04 (VN1203), and the NA of the mouse-adapted H1N1 influenza virus A/Puerto Rico/8/34 (PR8) in the VSV⌬G vector restored the ability of the recombinant virus to replicate in cell culture, without the requirement for the addition of trypsin. We show here that this recombinant virus vaccine candidate was nonpathogenic in mice when given by either the intramuscular or intranasal route of immunization and that the in vivo replication of VSV⌬G-H5N1 is profoundly attenuated. This recombinant virus also provided protection against lethal H5N1 infection after a single dose. This novel approach to vaccination against HPAIVs may be widely applicable to other emerging strains of influenza virus. IMPORTANCEPreparation for a potentially catastrophic influenza pandemic requires novel influenza vaccines that are safe, can be produced and administered quickly, and are effective, both soon after administration and for a long duration. We have created a new influenza vaccine that utilizes an attenuated vesicular stomatitis virus (VSV) vector, to deliver and express influenza virus proteins against which vaccinated animals develop potent antibody responses. The influenza virus hemagglutinin and neuraminidase proteins, expressed on the surface of VSV particles, allowed this vaccine to grow in cell culture and induced a potent antibody response in mice that was effective against infection with a lethal influenza virus. The mice showed no adverse reactions to the vaccine, and they were protected against an otherwise lethal influenza infection after only 14 days postvaccination and after as many as 140 days postvaccination. The ability to rapidly produce this safe and effective vaccine in cell culture is additionally advantageous.

show abstract

Section: Discussionmentioning

confidence: 99%

A Viable Recombinant Rhabdovirus Lacking Its Glycoprotein Gene and Expressing Influenza Virus Hemagglutinin and Neuraminidase Is a Potent Influenza Vaccine

Ryder

Buonocore

Vogel

et al. 2015

J Virol

View full text Add to dashboard Cite

show abstract

“…The use of cores from lentiviral human immunodeficiency virus (HIV) and gammaretroviruses such as murine leukemia virus (MLV) predominate in the influenza pseudotype literature. Recent development of systems involving rhabdoviruses, in particular the vesicular stomatitis virus (VSV), has also been used to produce pseudotype cores with promising results (3,4).…”

Section: Cores and Reportersmentioning

confidence: 99%

Pseudotype-Based Neutralization Assays for Influenza: A Systematic Analysis

et al. 2015

View full text Add to dashboard Cite

The use of vaccination against the influenza virus remains the most effective method of mitigating the significant morbidity and mortality caused by this virus. Antibodies elicited by currently licensed influenza vaccines are predominantly hemagglutination-inhibition (HI)-competent antibodies that target the globular head of hemagglutinin (HA) thus inhibiting influenza virus entry into target cells. These antibodies predominantly confer homosubtypic/strain specific protection and only rarely confer heterosubtypic protection. However, recent academia or pharma-led R&D toward the production of a “universal vaccine” has centered on the elicitation of antibodies directed against the stalk of the influenza HA that has been shown to confer broad protection across a range of different subtypes (H1–H16). The accurate and sensitive measurement of antibody responses elicited by these “next-generation” influenza vaccines is, however, hampered by the lack of sensitivity of the traditional influenza serological assays HI, single radial hemolysis, and microneutralization. Assays utilizing pseudotypes, chimeric viruses bearing influenza glycoproteins, have been shown to be highly efficient for the measurement of homosubtypic and heterosubtypic broadly neutralizing antibodies, making them ideal serological tools for the study of cross-protective responses against multiple influenza subtypes with pandemic potential. In this review, we will analyze and compare literature involving the production of influenza pseudotypes with particular emphasis on their use in serum antibody neutralization assays. This will enable us to establish the parameters required for optimization and propose a consensus protocol to be employed for the further deployment of these assays in influenza vaccine immunogenicity studies.

show abstract

“…Different viral cores are commonly used: vesicular stomatitis virus [93], gammaretroviruses (e.g., murine leukemia virus [MLV]) [94] and lentivirus (HIV) [95,96]. Lentiviral cores and lentiviral vectors are particularly useful since lentiviruses can integrate into the cellular genome of dividing and nondividing cells and this has led to their use in gene therapy and the development of many lentiviral vectors (reviewed in Sakuma et al) [97].…”

Section: Pseudotype Particlesmentioning

confidence: 99%

The Application of Pseudotypes to Influenza Pandemic Preparedness

2015

View full text Add to dashboard Cite

Human and animal populations are constantly exposed to multiple influenza strains due to zoonotic spillover and rapid viral evolution driven by intrinsic error-prone replication and immunological pressure. In this context, antibody responses directed against the hemagglutinin protein on the surface of the virus are of importance since they have been shown to correlate with protective immunity. Serological techniques, detecting these responses, play a critical role in influenza pandemic preparedness in particular with regard to the measurement of vaccine immunogenicity. As the recent human pandemics (H1N1) and avian influenza outbreaks (H5 and H7) have demonstrated, there is an urgent need to be better prepared to assess the contribution of the antibody response to protection against newly emerged viruses and to evaluate the extent of pre-existing heterosubtypic immunity in populations. This review compares pseudotype-based assays with wild-type and viruslike particle virus assays and discusses their place in the pandemic preparedness against the influenza virus. It additionally addresses the state-of-the-art developments of pseudotypebased assays (chimeric hemagglutinins, multiplex and post-attachment) including the development and future deployment of assay kits and approaches toward standardization to both preclinical and clinical endpoints. Progress toward the development of an influenza pseudotype library for the purposes of pandemic preparedness is also outlined and discussed.

show abstract

A vesicular stomatitis pseudovirus expressing the surface glycoproteins of influenza A virus

Cited by 13 publications

References 19 publications

A Viable Recombinant Rhabdovirus Lacking Its Glycoprotein Gene and Expressing Influenza Virus Hemagglutinin and Neuraminidase Is a Potent Influenza Vaccine

A Viable Recombinant Rhabdovirus Lacking Its Glycoprotein Gene and Expressing Influenza Virus Hemagglutinin and Neuraminidase Is a Potent Influenza Vaccine

Pseudotype-Based Neutralization Assays for Influenza: A Systematic Analysis

The Application of Pseudotypes to Influenza Pandemic Preparedness

Contact Info

Product

Resources

About